Connect Biopharma (NASDAQ:CNTB – Get Free Report) and Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Volatility & Risk
Connect Biopharma has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500. Comparatively, Artiva Biotherapeutics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for Connect Biopharma and Artiva Biotherapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Connect Biopharma | 1 | 0 | 8 | 0 | 2.78 |
| Artiva Biotherapeutics | 1 | 0 | 4 | 1 | 2.83 |
Connect Biopharma presently has a consensus price target of $5.88, indicating a potential upside of 670.90%. Artiva Biotherapeutics has a consensus price target of $39.00, indicating a potential upside of 529.03%. Given Connect Biopharma’s higher probable upside, equities analysts clearly believe Connect Biopharma is more favorable than Artiva Biotherapeutics.
Profitability
This table compares Connect Biopharma and Artiva Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Connect Biopharma | N/A | -165.41% | -121.58% |
| Artiva Biotherapeutics | N/A | -53.86% | -48.16% |
Earnings & Valuation
This table compares Connect Biopharma and Artiva Biotherapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Connect Biopharma | $60,000.00 | 799.82 | -$55.48 million | ($1.19) | -0.64 |
| Artiva Biotherapeutics | $250,000.00 | 1,212.47 | -$83.86 million | ($3.30) | -1.88 |
Connect Biopharma has higher earnings, but lower revenue than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
58.7% of Connect Biopharma shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Artiva Biotherapeutics beats Connect Biopharma on 7 of the 13 factors compared between the two stocks.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
